blood component
Recently Published Documents


TOTAL DOCUMENTS

720
(FIVE YEARS 189)

H-INDEX

32
(FIVE YEARS 5)

2022 ◽  
Vol 11 (2) ◽  
pp. 356
Author(s):  
James H. Lantry ◽  
Phillip Mason ◽  
Matthew G. Logsdon ◽  
Connor M. Bunch ◽  
Ethan E. Peck ◽  
...  

Modern approaches to resuscitation seek to bring patient interventions as close as possible to the initial trauma. In recent decades, fresh or cold-stored whole blood has gained widespread support in multiple settings as the best first agent in resuscitation after massive blood loss. However, whole blood is not a panacea, and while current guidelines promote continued resuscitation with fixed ratios of blood products, the debate about the optimal resuscitation strategy—especially in austere or challenging environments—is by no means settled. In this narrative review, we give a brief history of military resuscitation and how whole blood became the mainstay of initial resuscitation. We then outline the principles of viscoelastic hemostatic assays as well as their adoption for providing goal-directed blood-component therapy in trauma centers. After summarizing the nascent research on the strengths and limitations of viscoelastic platforms in challenging environmental conditions, we conclude with our vision of how these platforms can be deployed in far-forward combat and austere civilian environments to maximize survival.


2021 ◽  
Vol 9 (2) ◽  
pp. 106-111
Author(s):  
Renata Primasari

  Abstract This leukodepleted PRC (PRC-LD) is considered capable of preventing reactions related to blood transfusions because it contains only a small number of leukocytes. The blood component of PRC-LD has also been shown to prevent or reduce transfusion reactions. Leukodepleted is a procedure to reduce the number of leukocytes in the blood or blood components to be transfused to a minimum of <1x106 leukocytes/unit (European standard) or reduce the number of leukocytes >99%. The purpose of this study was to see the difference in leukocyte values ​​in the PRC and PRC-LD components. The method used is analytic, namely research that aims to determine the relationship between variables within the scope of the laboratory. The method used is a comparative study. This study used 30 samples of PRC products and 30 samples of Leucodepleted PRC products at UTD PMI Surabaya City with 450 cc bags. The study was conducted in October - December 2019. The result was that the leukocyte value in the PRC blood component contained blood quality that did not meet the specifications as many as 30 bags (100%) had leukocyte levels >1x106 per bag. Meanwhile, the blood component of PRC-LD contains blood quality that meets the specifications as many as 30 bags (100%), having leukocyte levels <1x106 per bag. Conclusion The quality of PRC Leukodepleted blood component products, the quality of leukocyte levels that meet the specifications, there are 30 blood bags (100%). Keywords: Packed Red Cells Leukodepleted


Author(s):  
Mamta Sharma ◽  
Rajkumar .

Disseminated intravascular coagulation is a life threatening complication of ectopic pregnancy. It results from washing out of all important procoagulants. This is basically a state of increased propensity for clot formation triggered by a variety of stimuli related to such diverse disorders as sepsis ,endothelial cell damage (heat stroke and shock), obstetrical complication (abruptio placenta, amniotic fluid embolism, severe preeclampsia and retained intrauterine dead foetus). A case of disseminated intravascular coagulation with septicemic shock following laprotomy for ectopic pregnancy is reported. She was treated by vasopressors, broad spectrum antibiotic and aggressive blood and blood component therapy.


2021 ◽  
Vol 23 (6) ◽  
pp. 1307-1318
Author(s):  
T. V. Glazanova ◽  
E. R. Shilova ◽  
A. V. Chechetkin ◽  
L. N. Bubnova

Transfusions of blood provide essential therapeutic measures in a number of pathological conditions. However, when carrying out blood component therapy, it is important to consider probability of post-transfusion complications. Most of them are immune-mediated side effects. The unfavorable consequences of blood transfusions can manifest at long-range time periods, and pathogenesis of these phenomena may be associated not only with the presence of alloantibodies. They may be caused by alloimmunization to HLA antigens, leukocyte factors, including cytokines, products of leukocyte degranulation, as well as storage-related erythrocyte damage («storage lesion»), immunomodulatory properties of extracellular vesicles or microparticles derived from blood components, and other factors. Despite significant number of publications on this issue, a lot of unresolved issues still remain, concerning transfusion-related effects of blood components on the immune system of recipients. The review article provides the results of current studies in this area. We present and discuss the results of current studies and the features of transfusion-mediated immunomodulation (TRIM) revealed over recent years, when transfusing different blood components. The role of plasma factors, microparticles, platelets and erythrocytes, HLA sensitization and microchimerism in the development of TRIM is highlighted, the data on occurrence and clinical features of TRIM in perioperative period are presented. A separate section of the review provides information about recent clinical studies, devoted to the issues of TRIM in different clinical cohorts, including newborns, patients with malignant neoplasms, immunocompromised patients after heart and vascular surgery. The data on TRIM incidence in the patients with exhausted immune system due to previous disease or treatment, severe comorbidity, extensive surgical thoracic/abdominal intervention and artificial circulation are also in scope. As based on the studies performed, the role of distinct measures, e.g., washing of erythrocyte concentrates, leukodepletion, and gamma irradiation are discussed in view of potential TRIM prevention. The results of published research do not allow us to draw definite conclusions about the effects of blood component transfusion on the immune system of recipients with respect to differences between the studied groups of patients, characteristics of the studied disorders and clinical situations, diversity of hemocomponents, as well as varying standards of transfusion therapy adopted in different countries. However, the systematic literature review may provide some guidance in transfusion-mediated immune modulation.


Coatings ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1555
Author(s):  
Abduladheem Turki Jalil ◽  
Shameen Ashfaq ◽  
Dmitry Olegovich Bokov ◽  
Amer M. Alanazi ◽  
Kadda Hachem ◽  
...  

In this work, a novel structure of an all-optical biosensor based on glass resonance cavities with high detection accuracy and sensitivity in two-dimensional photon crystal is designed and simulated. The free spectral range in which the structure performs well is about FSR = 630 nm. This sensor measures the concentration of glucose in human urine. Analyses to determine the glucose concentration in urine for a normal range (0~15 mg/dL) and urine despite glucose concentrations of 0.625, 1.25, 2.5, 5 and 10 g/dL in the wavelength range 1.326404~1.326426 μm have been conducted. The detection range is RIU = 0.2 × 10−7. The average bandwidth of the output resonance wavelengths is 0.34 nm in the lowest case. In the worst case, the percentage of optical signal power transmission is 77% with an amplitude of 1.303241 and, in the best case, 100% with an amplitude of 1.326404. The overall dimensions of the biosensor are 102.6 µm2 and the sensitivity is equal to S = 1360.02 nm/RIU and the important parameter of the Figure of Merit (FOM) for the proposed biosensor structure is equal to FOM = 1320.23 RIU−1.


2021 ◽  
pp. 000313482110497
Author(s):  
Janet S. Lee ◽  
Abid D. Khan ◽  
Franklin L. Wright ◽  
Robert C. McIntyre ◽  
Warren C. Dorlac ◽  
...  

Background Military data demonstrating an improved survival rate with whole blood (WB) have led to a shift toward the use of WB in civilian trauma. The purpose of this study is to compare a low-titer group O WB (LTOWB) massive transfusion protocol (MTP) to conventional blood component therapy (BCT) MTP in civilian trauma patients. Methods Trauma patients 15 years or older who had MTP activations from February 2019 to December 2020 were included. Patients with a LTOWB MTP activation were compared to BCT MTP patients from a historic cohort. Results 299 patients were identified, 169 received LTOWB and 130 received BCT. There were no differences in age, gender, or injury type. The Injury Severity Score was higher in the BCT group (27 vs 25, P = .006). The LTOWB group had a longer transport time (33 min vs 26 min, P < .001) and a lower arrival temperature (35.8 vs 36.1, P < .001). Other hemodynamic parameters were similar between the groups. The LTOWB group had a lower in-hospital mortality rate compared to the BCT group (19.5% vs 30.0%, P = .035). There were no differences in total transfusion volumes at 4 hours and 24 hours. No differences were seen in transfusion reactions or hospital complications. Multivariable logistic regression identified ISS, age, and 24-hour transfusion volume as predictors of mortality. Discussion Resuscitating severely injured trauma patient with LTOWB is safe and may be associated with an improved survival.


Pathogens ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1499
Author(s):  
Roberta Maria Fachini ◽  
Rita Fontão-Wendel ◽  
Ruth Achkar ◽  
Patrícia Scuracchio ◽  
Mayra Brito ◽  
...  

(1) Background: We reviewed the logistics of the implementation of pathogen reduction (PR) using the INTERCEPT Blood System™ for platelets and the experience with routine use and clinical outcomes in the patient population at the Sírio-Libanês Hospital of São Paulo, Brazil. (2) Methods: Platelet concentrate (PC), including pathogen reduced (PR-PC) production, inventory management, discard rates, blood utilization, and clinical outcomes were analyzed over the 40 months before and after PR implementation. Age distribution and wastage rates were compared over the 10 months before and after approval for PR-PC to be stored for up to seven days. (3) Results: A 100% PR-PC inventory was achieved by increasing double apheresis collections and production of double doses using pools of two single apheresis units. Discard rates decreased from 6% to 3% after PR implementation and further decreased to 1.2% after seven-day storage extension for PR-PCs. The blood utilization remained stable, with no increase in component utilization. A significant decrease in adverse transfusion events was observed after the PR implementation. (4) Conclusion: Our experience demonstrates the feasibility for Brazilian blood centers to achieve a 100% PR-PC inventory. All patients at our hospital received PR-PC and showed no increase in blood component utilization and decreased rates of adverse transfusion reactions.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1778-1778
Author(s):  
Samar Kulkarni ◽  
John Murray ◽  
James Clarke ◽  
Mike Dennis ◽  
Amit Patel ◽  
...  

Abstract Use of Cryopreserved Allogeneic PBSC Results in Delayed Engraftment And Increased Incidence of Poor Graft Function Introduction: During COVID Pandemic, national and international transplant centres agreed to use cryopreserve the donor PBSC as a safer option to deliver allogeneic transplants. Published data suggests that use of cryopreserved allogeneic PBSC is safe and comparable to use of fresh PBSC but cryopreservation of stem cells may lead to cell loss and hence efficacy. During COVID pandemic, use of cryopreserved allogeneic PBSC was adopted as policy on 01/06/2020. This look back analysis evaluates the impact of change in policy. Aims: Evaluate Engraftment time, compare with historical data, blood component support, and use of growth factors Methods and Materials: Data was collected from health records (paper and electronic) and laboratory records. Transplant features and engraftment kinetics were analysed. Results: Group A June 2020 to November 2020, 19 patients [M: 13; F: 6; median age: 50yr (range: 23-69)] who received cryopreserved allogeneic PBSC were compared to 35 patients [M:24; F:11; median age: 59yr (range: 21-71)] receiving fresh allogeneic PBSC for engraftment kinetics. There were no differences between two groups regarding underlying diagnosis (p=0.31), sex mismatch, CMV mismatch, blood group mismatch, reduced intensity conditioning [RIC](p=0.28), type of donor (p=0.98) or use of Alemtuzumab (p=0.88). Median infused Cell dose in group A was 5.3 (3.4-7.16) and in group B 4.9 (1.03-6.85), [p=0.11]. Neutrophil engraftment was significantly faster with fresh PBSC as compared to cryopreserved PBSC (16d vs. 25d, p=0.0025) predominantly with MUD (18d vs. 27d, p=0.009) and RIC (16d vs. 25d, p=0.009). Platelet engraftment to 25 was faster with fresh PBSC (13d vs. 20d, p=0.021) with delayed engraftment in MUD (20d vs. 13d, p=0.006) and RIC (23d vs. 13d, p=0.039). Day to engraftment per unit CD34 was shorter with fresh PBSC for neutrophils (median: 3.2, range: 2.0-7.7 vs. 5.3, range: 2.5-16.7; p=0.006) and platelets (median: 2.4, range: 1.7-25 vs. 3.8, range: 2.2-25; p=0.001) but only for MUD. This suggests 35-40% less efficiency with use of cryopreserved PBSC. There was no difference in the need for transfusion support [RBCs (6 units vs. 3 units, p=0.32); platelets (5 pools vs. 7 pools, p=0.33)]. G-CSF use was higher with cryopreserved PBSC in RIC (54% vs. 20%, p=0.031). Two patients experienced TRM before day 90 (3.7%). At day 90, 17/52 (32.7%) had cytopenia in one lineage and 8/52 (16%) had cytopenia in more than one lineage. Delayed engraftment was observed in 10 of 33 patients (30.3%) transplanted in 2020 and the only significant association was use of cryopreserved PBSC (0% vs. 53%, p=0.001). There was no difference in the incidence of aGVHD, hepatic VOD, microangiopathy and bacterial infections. Numbers are not sufficient to make disease specific comparisons. Conclusion: Cryopreserved PBSC result in delayed neutrophil and platelet engraftment predominantly with MUDS and RIC. Incidence of delayed engraftment and poor graft function is higher. Per unit CD34 dose, cryopreserved PBSC are 30-40% less efficient to achieve engraftment. Delayed engraftment with cryopreserved PBSC especially in MUD raises the possibility that time from harvest to cryopreservation contributes to reduced efficacy. Based on these findings it was decided to infuse higher CD34 dose (6-7x10^6/kg as compared to usual 4-5x10^6/kg) for cryopreserved MUD PBSC. Disclosures Bloor: Kite, a Gilead Company: Honoraria; Novartis: Honoraria.


Sign in / Sign up

Export Citation Format

Share Document